Noblemeds And Surgicals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 12-12-2024
- Paid Up Capital ₹ 1.00 M
as on 12-12-2024
- Company Age 5 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -8.27%
(FY 2022)
- Profit -44.59%
(FY 2022)
- Ebitda -792.88%
(FY 2022)
- Net Worth 6.37%
(FY 2022)
- Total Assets -47.80%
(FY 2022)
About Noblemeds And Surgicals
The Company is engaged in the Home Appliances Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Lalchand Daswani and Manju Daswani serve as directors at the Company.
- CIN/LLPIN
U51397MH2019PTC322100
- Company No.
322100
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Mar 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Nagpur, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Noblemeds And Surgicals Private Limited offer?
Noblemeds And Surgicals Private Limited offers a wide range of products and services, including Brain & Nervous System Drugs, Antidepressant & Anti Anxiety Medicines, TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Anti Infective Drugs & Medicines, Anti Allergic Drug, Sexual Wellness Products, Contraceptives, Anti Cancer Injection, Forceps & Graspers.
Who are the key members and board of directors at Noblemeds And Surgicals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Lalchand Daswani  | Director | 01-Mar-2019 | Current |
| Manju Daswani | Director | 01-Mar-2019 | Current |
Financial Performance of Noblemeds And Surgicals.
Noblemeds And Surgicals Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 8.27% decrease. The company also saw a substantial fall in profitability, with a 44.59% decrease in profit. The company's net worth moved up by a moderate rise of 6.37%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Noblemeds And Surgicals?
Unlock access to Noblemeds And Surgicals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Avtar Surgical And Pharmaceuticals Private LimitedActive 3 years 2 monthsLalchand Daswani and Manju Daswani are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Noblemeds And Surgicals?
Unlock and access historical data on people associated with Noblemeds And Surgicals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Noblemeds And Surgicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Noblemeds And Surgicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
